- Home
- ELDN vs CERS Comparison
ELDN vs CERS Comparison
Compare ELDN & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- CERS
- Stock Information
- Founded
- ELDN 2004
- CERS 1991
- Country
- ELDN United States
- CERS United States
- Employees
- ELDN N/A
- CERS N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- CERS EDP Services
- Sector
- ELDN Health Care
- CERS Technology
- Exchange
- ELDN Nasdaq
- CERS Nasdaq
- Market Cap
- ELDN 288.5M
- CERS 286.0M
- IPO Year
- ELDN N/A
- CERS 1997
- Fundamental
- Price
- ELDN $4.09
- CERS $1.85
- Analyst Decision
- ELDN Strong Buy
- CERS Buy
- Analyst Count
- ELDN 1
- CERS 3
- Target Price
- ELDN $16.00
- CERS $3.17
- AVG Volume (30 Days)
- ELDN 520.7K
- CERS 1.4M
- Earning Date
- ELDN 11-12-2024
- CERS 03-04-2025
- Dividend Yield
- ELDN N/A
- CERS N/A
- EPS Growth
- ELDN N/A
- CERS N/A
- EPS
- ELDN N/A
- CERS N/A
- Revenue
- ELDN N/A
- CERS $176,229,000.00
- Revenue This Year
- ELDN N/A
- CERS $21.42
- Revenue Next Year
- ELDN N/A
- CERS $11.12
- P/E Ratio
- ELDN N/A
- CERS N/A
- Revenue Growth
- ELDN N/A
- CERS 14.71
- 52 Week Low
- ELDN $1.52
- CERS $1.38
- 52 Week High
- ELDN $5.54
- CERS $2.59
- Technical
- Relative Strength Index (RSI)
- ELDN 47.03
- CERS 60.59
- Support Level
- ELDN $3.68
- CERS $1.74
- Resistance Level
- ELDN $4.19
- CERS $1.89
- Average True Range (ATR)
- ELDN 0.32
- CERS 0.10
- MACD
- ELDN -0.04
- CERS 0.03
- Stochastic Oscillator
- ELDN 31.54
- CERS 89.74
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.